共 258 条
[1]
Wiviott SD(2022)10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022 Diabetes Care 45 S144-S174
[2]
Raz I(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-357
[3]
Bonaca MP(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[4]
Mosenzon O(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[5]
Kato ET(2018)Economic costs of diabetes in the US in 2017 Diabetes Care 41 917-928
[6]
Cahn A(2021)Insulin resistance, cardiovascular stiffening and cardiovascular disease Metabolism 119 1357-1364
[7]
Silverman MG(2020)Diabetes and coronary artery disease: not just a risk factor Heart 106 2180-2184
[8]
Zelniker TA(2000)Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus Circulation 102 2-42
[9]
Kuder JF(2014)Assessment of pancreatic beta-cell function: review of methods and clinical applications Curr Diabetes Rev 10 108-304
[10]
Murphy SA(2020)Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China Cardiovasc Diabetol 19 299-105